Although the findings obtained have not yet been reported, the efficacy of KPL-716, a monoclonal antibody against OSMRβ (oncostatin M receptor β, a subunit for IL-31 receptor), was evaluated in a pilot phase II study on patients with disease-accompanying itch, including those with plaque psoriasis [159]. Here, OSMR is linked to psoriasis vulgaris.